Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes (EXPAND)
An Open, 5-year Registry Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results and Associated Patient Outcomes
Sponsor: Castle Biosciences Incorporated
Terminated
Study goals were met with smaller that expected study cohort. Last patient completed the study June 201
Other terminated trials from Castle Biosciences Incorporated
More terminations from Castle Biosciences Incorporated
Listed as NCT02355587, this observational or N/A phase trial focuses on Cutaneous Melanoma and remains terminated or withdrawn. Sponsored by Castle Biosciences Incorporated, it has been updated 9 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Nov 2021 — Dec 2021 [monthly]
Terminated
Status: Active Not Recruiting → Terminated
-
Jan 2021 — Nov 2021 [monthly]
Active Not Recruiting
▶ Show 4 earlier versions
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting
-
Jun 2018 — Jul 2020 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Castle Biosciences Incorporated
For direct contact, visit the study record on ClinicalTrials.gov .